CTVA · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $17.40B | $16.91B | $17.23B | $17.45B | $15.65B | $14.22B | $13.85B | $14.29B |
| Cost of Revenue | $9.17B | $9.53B | $9.92B | $10.44B | $9.22B | $8.51B | $8.57B | $9.95B |
| Research & Development | $1.47B | $1.40B | $1.34B | $1.22B | $1.19B | $1.14B | $1.15B | $1.35B |
| Selling, General & Administrative | $3.49B | $3.20B | $3.18B | $3.17B | $3.21B | $3.04B | $3.06B | $3.04B |
| Other Income / (Expense) | -$570.00M | -$300.00M | -$448.00M | -$60.00M | $1.35B | $212.00M | $215.00M | $249.00M |
| Income Before Taxes | $1.69B | $1.27B | $1.09B | $1.43B | $2.35B | $675.00M | -$316.00M | -$6.81B |
| Provision for Income Taxes | $484.00M | $412.00M | $152.00M | $210.00M | $524.00M | -$81.00M | -$46.00M | -$31.00M |
| Net Income | $1.09B | $907.00M | $735.00M | $1.15B | $1.76B | $681.00M | -$959.00M | -$5.07B |
| Basic EPS | $1.60 | $1.31 | $1.04 | $1.59 | $2.39 | $0.91 | -$1.28 | -$6.76 |
| Diluted EPS | $1.60 | $1.30 | $1.03 | $1.58 | $2.37 | $0.91 | -$1.28 | -$6.76 |
| Basic Shares Outstanding | 680.00M | 693.70M | 709.00M | 720.80M | 735.90M | 748.70M | 749.50M | 749.40M |
| Diluted Shares Outstanding | 681.40M | 696.00M | 711.90M | 724.50M | 741.60M | 751.20M | 749.50M | 749.40M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $3.74 | $3.68 | $3.80 | 8 | ↑4 ↓3 |
| Dec 2027 | $4.02 | $3.52 | $4.28 | 9 | ↑2 ↓4 |
| Dec 2028 | $4.50 | $4.08 | $4.82 | 5 | ↑1 ↓2 |
| Dec 2029 | $4.35 | $4.35 | $4.35 | 1 | ↑1 ↓0 |